ICI-aOA versus ICI-IA
| ICI-aOA | ICI-IA (Ghosh et al5) | |
| Demographics | ||
| Mean age (years) Sex | 66 (51–81) 53% male | 63 (52–74) 61% male |
| Tumor type | Melanoma (28%) NSCLC (14%) RCC (17%) | Melanoma (57%) NSCLC (22%) RCC (7%) |
| Cancer immunotherapy | PD-1/PD-L1i monotherapy (86%) CTLA-4i monotherapy (0%) | PD-1/PD-L1i monotherapy (78%) CTLA-4i monotherapy (5%) |
| Malignancy outcome | Complete response (44%) Partial response (14%) Stable disease (13%) Progressive disease (11%) | Complete response (20%) Partial response (33%) Stable disease (21%) Progressive disease (27%) |
| Median months to onset | 5 months (range 0–34) | 4 months (range 0–53) |
| Joint distribution | Small joint (first CMC, DIPs, PIPs, etc) (25%) Large joint (53%) Spine (14%) | Small joint (RA distribution: MCPs, PIPs, etc) (65%) Large joint (22%) Spine (13%) |
| Joint count | Polyarticular (67%) | Polyarticular (49%) |
| Serologies (% of total tested) | 19% (5/27) RF and/or CCP 32% (7/22) ANA | 9% (25/270) RF and/or CCP 30% (57/193) ANA |
| Therapeutics | No medicinal therapy (20%) NSAIDs (20%) Local CSIs (43%) Systemic corticosteroids (11%) Non-steroidal DMARDs (3%) | No medicinal therapy (55%) NSAIDs (20%) Local CSIs (14%) Systemic corticosteroids (74%) Non-steroidal DMARDs (31%) |
| Other irAEs, any grade | 58% | 52% |
| Arthropathy outcome | Improved or controlled with therapy 89% | Improved or controlled with therapy 63% |
ANA, antinuclear antibody; aOA, activated osteoarthritis; CCP, cyclic citrullinated peptide; CMC, carpometacarpal; CSI, corticosteroid injection; CTLA-4i, cytotoxic T lymphocyte-associated protein 4 inhibitor; DIP, distal interphalangeal; DMARD, disease modifying antirheumatic drug; ICI, immune checkpoint inhibitor; ICI-aOA, ICI-activated osteoarthritis; ICI-IA, ICI-inflammatory arthritis; irAE, immune-related adverse event; MCP, metacarpophalangeal; NSAID, non-steroidal anti-inflammatory drug; NSCLC, non-small cell lung carcinoma; PD-1/PD-L1i, programed cell death protein 1 inhibitor; PIP, proximal interphalangeal; RA, rheumatoid arthritis; RCC, renal cell carcinoma; RF, rheumatoid factor.